| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.045 | 0.5 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.5 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.029 | 0.5 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.5 |